BS_KVAJYZ6F
Glial-neuronal tumor NOS
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Glial-neuronal tumor NOS
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Glial-neuronal tumor NOS
- overall_survival_months
- 60.21681997371879
- age_years
- 15.099
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.603
- OXIDATIVE_PHOSPHORYLATION+0.566
- MYC_TARGETS_V1+0.417
- PEROXISOME+0.315
- PI3K_AKT_MTOR_SIGNALING+0.283
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.269
- ANDROGEN_RESPONSE+0.248
- FATTY_ACID_METABOLISM+0.246
- ADIPOGENESIS+0.234
- MTORC1_SIGNALING+0.234
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.464
- ANGIOGENESIS-0.373
- APICAL_JUNCTION-0.281
- WNT_BETA_CATENIN_SIGNALING-0.272
- KRAS_SIGNALING_DN-0.271
- APICAL_SURFACE-0.265
- COAGULATION-0.243
- ESTROGEN_RESPONSE_LATE-0.225
- CHOLESTEROL_HOMEOSTASIS-0.213
- HYPOXIA-0.204
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R155 | — | — | 0.844 |
| 2 | BS_CZ3NA7KV | Supratentorial Ependymoma | — | 0.837 |
| 3 | BS_WYERXS4G | Supratentorial Ependymoma | — | 0.828 |
| 4 | BS_4NWHYH53 | Supratentorial Ependymoma | — | 0.826 |
| 5 | BS_CHDGRYHJ | Med | Medulloblastoma | 0.818 |
| 6 | SJBT031392_D1.RNA-Seq | EPN | EPN Tumor | 0.811 |
| 7 | BS_3F4FQJMR | EPN | Supratentorial EPN | 0.809 |
| 8 | SJEPD030146_D1.RNA-Seq | EPN | Supratentorial EPN | 0.808 |
| 9 | MNG389 | — | — | 0.807 |
| 10 | MNG1213 | — | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.603 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.566 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.417 | Inavolisib | — uncovered |
| PEROXISOME | 0.315 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.283 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.269 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.248 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.246 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.234 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.234 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.229 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.216 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.189 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.173 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.163 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.157 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.109 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.085 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.068 | Inavolisib | — uncovered |